• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form PRE 14A filed by Prothena Corporation plc

    9/25/25 4:30:36 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRTA alert in real time by email
    PRE 14A 1 ny20053507x1_pre14a.htm PRE 14A

    TABLE OF CONTENTS

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 14A
    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934
     
     
     
     
     
     
     
     
     
     
    Filed by the Registrant
     
     
    ☒
     
     
    Filed by a Party other than the Registrant
     
     
    ☐
     
     
     
     
     
     
     
     
     
     
    Check the appropriate box:
    ☒
    Preliminary Proxy Statement
    ☐
    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐
    Definitive Proxy Statement
    ☐
    Definitive Additional Materials
    ☐
    Soliciting Material Pursuant to § 240.14a-12
    PROTHENA CORPORATION PUBLIC LIMITED COMPANY
    (Name of registrant as specified in its charter)
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)
    Payment of Filing Fee (Check all boxes that apply):
     
     
     
     
    ☒
     
     
    No fee required.
     
     
     
     
    ☐
     
     
    Fee paid previously with preliminary materials.
     
     
     
     
    ☐
     
     
    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
     
     
     
     

    TABLE OF CONTENTS


     
    [ ], 2025
    Dear Shareholder:
    You are cordially invited to attend the Extraordinary General Meeting of Shareholders (the “EGM”) of Prothena Corporation plc (the “Company”) to be held on Wednesday, November 19, 2025, at 4:00 p.m. local time, at the offices of A&L Goodbody LLP, 25 North Wall Quay, Dublin 1, D01 H104, Ireland.
    Details of the business to be presented at the EGM may be found in the Notice of Extraordinary General Meeting of Shareholders and the Proxy Statement accompanying this letter. At the EGM, we are asking shareholders to approve a reduction of our Company capital to facilitate the creation of distributable reserves. The reduction of capital will give our Board of Directors greater flexibility with respect to its ability to make future distributions to shareholders, including by way of a potential share redemption program as referenced in our press release dated August 4, 2025.
    We hope that you will participate in the meeting by voting through acceptable means as described in this Proxy Statement as promptly as possible. Your vote is important – so please exercise your right.
    Sincerely,
     
     
     
     
     
     
     

     
     
     

     
     
     
    Daniel G. Welch
    Chair of the Board
     
     
    Gene G. Kinney Ph.D.
    President and Chief Executive Officer, Director
     
     
     
     
     
     
     
     
    This Proxy Statement and the enclosed proxy card are being made available to shareholders on or about [ ], 2025.

    TABLE OF CONTENTS

     
     
     
     
     
     
     
    PROTHENA CORPORATION PLC
     
     

     
     
     
     
     
     
     
     
    Registered in Ireland - No. 518146
    77 Sir John Rogerson’s Quay, Block C, Grand Canal
    Docklands, Dublin 2, D02 VK60, Ireland
     
    NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON NOVEMBER 19, 2025
    To the Shareholders of Prothena Corporation plc:
    NOTICE IS HEREBY GIVEN that an Extraordinary General Meeting of Shareholders (the “EGM”) of Prothena Corporation plc, an Irish public limited company (the “Company”), will be held on Wednesday, November 19, 2025, at 4:00 p.m. local time, at the offices of the Company’s legal counsel, A&L Goodbody LLP, 25 North Wall Quay, Dublin 1, D01 H104, Ireland, for the following purposes:
    1.
    To approve the reduction of Company capital to facilitate the creation of distributable reserves; and
    2.
    To transact such other business as may properly come before the EGM or any adjournment or postponement thereof.
    The text of Proposal No.1 is set out in the Proxy Statement accompanying this Notice. Pursuant to our Constitution and Irish law, Proposal No. 1 is being proposes as a special resolution requiring the approval of at least 75% of the votes cast at the EGM.
    Only shareholders who owned our ordinary shares at the close of business on September 24, 2025, may vote at the EGM. Each shareholder of record will be entitled to one vote per ordinary share on each matter submitted to a vote of the shareholders, as long as those shares are represented at the EGM, either in person or by proxy. Shareholders who are entitled to attend and vote at the EGM are entitled to appoint a proxy or proxies to attend and vote on their behalf at the EGM; such proxy is not required to be a shareholder of the Company.
    Our Board of Directors unanimously recommends that you vote FOR the approval of the reduction of the Company’s capital to facilitate the creation of distributable reserves, as described in Proposal No. 1.
    For the EGM, we have elected to use the internet as the primary means of providing our proxy materials to shareholders. Consequently, some shareholders may not receive paper copies of our proxy materials. We intend to send shareholders a Notice of Internet Availability of Proxy Materials with instructions for accessing the proxy materials and for voting via the internet. The Notice of Internet Availability of Proxy Materials will also provide the date, time, and location of the EGM; the matters to be acted upon at the meeting and the Board of Directors’ recommendation with regard to each matter; a toll-free number, an e-mail address, and a website where shareholders can request a paper or e-mail copy of our Proxy Statement and form of proxy card; information on how to access their proxy card; and information on how to attend the meeting and vote in person.
    You are cordially invited to attend the EGM, but whether or not you expect to attend in person, you are urged to complete, sign, and date your proxy card and return it by mail or follow the alternative voting procedures described in the Notice of Internet Availability of Proxy Materials or the proxy card.
     
     
     
     
     
     
     
     
     
     
    By Order of the Board of Directors
     
     
     
     
     

     
     
     
     
     
     
    Michael J. Malecek
    Chief Legal Officer & Company Secretary
    Dublin, Ireland
    [  ], 2025
     
     
     
     
     
     
     

    TABLE OF CONTENTS

    TABLE OF CONTENTS
     
     
     
    Page
    GENERAL INFORMATION
     
     
    1
    THE PROXY PROCESS AND SHAREHOLDER VOTING - QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING
     
     
    2
    PROPOSAL NO. 1 - APPROVAL OF A REDUCTION OF THE COMPANY’S CAPITAL TO FACILITATE THE CREATION OF DISTRIBUTABLE RESERVES
     
     
    6
    SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
     
     
    8
    HOUSEHOLDING OF PROXY MATERIALS
     
     
    10

    TABLE OF CONTENTS

     
     
     
     
     
     
     
    PROTHENA CORPORATION PLC
     
     

     
     
     
     
     
     
     
     
    Registered in Ireland - No. 518146
    77 Sir John Rogerson’s Quay, Block C, Grand Canal Docklands, Dublin 2, D02 VK60, Ireland
     
    PROXY STATEMENT
    FOR THE EXTRAORDINARY GENERAL
    MEETING OF SHAREHOLDERS
    TO BE HELD ON NOVEMBER 19, 2025
     
    GENERAL INFORMATION
    The Board of Directors of Prothena Corporation plc is soliciting your proxy to vote at the Extraordinary General Meeting of Shareholders to be held on Wednesday, November 19, 2025, at 4:00 p.m. local time, and any adjournment or postponement of that meeting (the “EGM”). The EGM will be held at the offices of the Company’s legal counsel, A&L Goodbody LLP, 25 North Wall Quay, Dublin 1, D01 H104, Ireland.
    We have elected to use the internet as our primary means of providing our proxy materials to shareholders. Accordingly, on or about [ ], 2025, we are making this Proxy Statement, the accompanying form of proxy card, and the accompanying Notice of Extraordinary General Meeting of Shareholders available on the internet and mailing a Notice of Internet Availability of Proxy Materials to shareholders of record as of close of business on September 24, 2025 (the “Record Date”). Brokers and other nominees who hold shares on behalf of beneficial owners will be sending their own similar notice. All shareholders as of the Record Date will have the ability to access our proxy materials on the website referred to in the Notice of Internet Availability of Proxy Materials or request to receive a printed set of the proxy materials. Instructions on how to request a printed copy by mail or electronically may be found in the Notice of Internet Availability of Proxy Materials and on the website referred to in the notice, including an option to request paper copies on an ongoing basis. We intend to mail this Proxy Statement, together with the accompanying form of proxy card and Notice of Extraordinary General Meeting of Shareholders, to those shareholders entitled to vote at the EGM who have properly requested paper copies of such materials.
    The only voting securities of Prothena are our ordinary shares, $0.01 par value per share (“ordinary shares”). There were 53,829,928 ordinary shares issued and outstanding as of the Record Date. A quorum of shareholders is necessary to hold a valid meeting and requires that the shareholders holding a majority of the issued and outstanding ordinary shares entitled to vote are present in person or represented by proxy at the EGM.
    In this Proxy Statement, we refer to Prothena Corporation plc as the “Company,” “Prothena,” “our,” “we,” or “us” and the Board of Directors as the “Board.” When we refer to Prothena’s fiscal year, we mean the 12-month period ending December 31 of the stated year. The contents of our website are not intended to be incorporated by reference in this Proxy Statement, and any references to our website herein are intended for textual references only.
     
     
     
     
     
     
     

     
     
     
     
     
    1
     
     
     
     
     
     
     

    TABLE OF CONTENTS

    THE PROXY PROCESS AND SHAREHOLDER VOTING
    QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING
     
     
     
     
     
     
     
    1.
     
     
    Who can vote at the EGM?
     
     
     
     
     
     
     
    Only shareholders of record at the close of business on the Record Date will be entitled to vote at the EGM. As of the Record Date, there were 53,829,928 ordinary shares issued and outstanding and entitled to vote.
    Shareholder of Record: Shares Registered in Your Name
    If, on the Record Date, your shares were registered directly in your name with the transfer agent for our ordinary shares, Computershare Trust Company, N.A., then you are a shareholder of record. As a shareholder of record, you may vote in person at the EGM or vote by proxy. Whether or not you plan to attend the EGM, we urge you to fill out and return the enclosed proxy card or vote by proxy over the telephone or on the internet as instructed below to ensure your vote is counted.
    Beneficial Owner: Shares Registered in the Name of a Broker, Bank, or Other Agent
    If, on the Record Date, your shares were not held in your name, but rather in an account at a brokerage firm, bank, dealer, or other similar organization, who in turn hold through The Depository Trust Company (“DTC”), then you are the beneficial owner of shares held in “street name” and these proxy materials are being forwarded to you by that organization. The organization holding your account is considered the shareholder of record for purposes of voting at the EGM. As a beneficial owner, you have the right to direct your broker or other agent on how to vote the shares in your account. You are also invited to attend the EGM. However, since you are not the shareholder of record, you may not vote your shares in person at the EGM unless you request and obtain a valid proxy card from your broker or other agent who is the record holder of the shares, authorizing you to vote at the EGM.
     
     
     
     
     
     
     
    2.
     
     
    What am I being asked to vote on?
     
     
     
     
     
     
     
    You are being asked to vote FOR the approval of a reduction of the Company’s capital to facilitate the creation of distributable reserves.
    In addition, you are entitled to vote on any other matters that are properly brought before the EGM. We are not aware of any other matter that will be presented for
    consideration at the EGM. If any other matter is properly brought before the EGM, the Board intends that one of the individuals named in the accompanying form of proxy card will vote on such matter in accordance with his or her discretion.
     
     
     
     
     
     
     
    3.
     
     
    How do I vote?
     
     
     
     
     
     
     
    You may vote by mail or follow any alternative voting procedure described on the proxy card or the Notice of Internet Availability of Proxy Materials. To use an alternative voting procedure, follow the instructions on each proxy card that you receive or on the Notice of Internet Availability of Proxy Materials.
    For Proposal No. 1, you may vote “FOR” or “AGAINST” or abstain from voting. The procedures for voting are as follows:
    Shareholder of Record: Shares Registered in Your Name
    If you are a shareholder of record, you may vote in person at the EGM. Alternatively, you may vote by proxy by mail, over the internet, or by telephone. Whether or not you plan to attend the EGM, we urge you to vote by proxy to
    ensure your vote is counted. Even if you have submitted a proxy before the EGM, you may still attend the EGM and vote in person. In such case, your previously submitted proxy will be disregarded.
    •
    To vote in person, come to the EGM and we will give you a ballot when you arrive.
    •
    To vote using the proxy card, simply complete, sign, and date the proxy card and return it promptly in the envelope provided. If you return your signed proxy card to us before the EGM, we will vote your shares as you direct.
    •
    To vote by proxy over the internet, follow the instructions provided on the proxy card or in the Notice of Internet Availability of Proxy Materials.
     
     
     
     
     
     
     
    2
     
     

     
     
    2025 PROXY STATEMENT FOR EXTRAORDINARY GENERAL MEETING
     
     
     
     
     
     
     

    TABLE OF CONTENTS

    THE PROXY PROCESS AND SHAREHOLDER VOTING
    QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING
    •
    To vote by telephone if you request printed copies of the proxy materials by mail, you may vote by proxy by calling the toll-free number found on the proxy card.
    Beneficial Owner: Shares Registered in the Name of Broker, Bank, or Other Agent
    If you are a beneficial owner of shares registered in the name of your broker, bank, or other agent, who in turn hold through DTC, you should have received a voting instruction card and voting instructions with these proxy
    materials from that organization rather than from us. Simply complete and mail the voting instruction card to ensure that your vote is counted, or follow such instructions to submit your vote by the internet or telephone, if the instructions provide for internet and telephone voting. To vote in person at the EGM, you must obtain a valid proxy from your broker, bank, or other agent. Follow the instructions from your broker, bank, or other agent included with these proxy materials, or contact your broker, bank, or other agent to request a proxy form.
     
     
     
     
     
     
     
    4.
     
     
    Who counts the votes?
     
     
     
     
     
     
     
    Broadridge Financial Solutions, Inc. (“Broadridge”) has been engaged as our independent agent to tabulate shareholder votes.
     
     
     
     
     
     
     
    5.
     
     
    How are votes counted?
     
     
     
     
     
     
     
    For Proposal No.1, an affirmative vote of 75 percent of the votes cast in person or by proxy at the EGM is required for approval.
    If your shares are held by a broker on your behalf (that is, in “street name”), please instruct your broker on how to vote your shares. If you do not provide voting instructions, your shares will not be voted on any proposal that is considered to be “non-routine” under NYSE rules, in which case the broker does not have discretionary authority to vote. This is called a “broker non-vote.”
    We have been advised by the NYSE that Proposal No. 1 is considered to be a “routine” matter, meaning that if you do not return voting instructions to your broker by its deadline, your shares may be voted by your broker in its discretion.
    As a result, we do not expect any broker non-votes on Proposal No. 1. Nevertheless, we strongly encourage you to provide voting instructions to your broker to ensure that your vote is counted on the proposal.
    If shareholders abstain from voting, including brokers holding their clients’ shares of record who cause abstentions to be recorded, these shares will be considered present and entitled to vote at the EGM and will be counted towards determining whether or not a quorum is present. Abstentions will not, however, be considered votes cast at the EGM.
    Because the approval of Proposal No.1 is based on the votes cast at the EGM, abstentions will not have any effect on the outcome of voting of the proposal.
     
     
     
     
     
     
     
    6.
     
     
    How many votes do I have?
     
     
     
     
     
     
     
    On each matter to be voted upon, you have one vote for each ordinary share you own as of the Record Date.
     
     
     
     
     
     
     
    7.
     
     
    Why did I receive a notice in the mail regarding the internet availability of proxy materials instead of a full set of proxy materials?
     
     
     
     
     
     
     
    Pursuant to rules of the U.S. Securities and Exchange Commission (the “SEC”), Irish law, and our Constitution, we have elected to provide access to our proxy materials on the internet. Accordingly, we are sending a Notice of Internet Availability of Proxy Materials to our shareholders. All shareholders will have the ability to access the proxy materials on the website referred to in the Notice of Internet Availability of Proxy Materials or request to receive a printed set of the proxy materials. Instructions on how to
    access the proxy materials on the internet or to request a printed copy may be found in the Notice of Internet Availability of Proxy Materials. In addition, shareholders may request to receive proxy materials in printed form by mail or electronically by email on an ongoing basis. We encourage shareholders to take advantage of the availability of the proxy materials on the internet to help reduce the environmental impact of the EGM.
     
     
     
     
     
     
     

     
     
    2025 PROXY STATEMENT FOR EXTRAORDINARY GENERAL MEETING
     
     
    3
     
     
     
     
     
     
     

    TABLE OF CONTENTS

    THE PROXY PROCESS AND SHAREHOLDER VOTING
    QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING
     
     
     
     
     
     
     
    8.
     
     
    How do I vote via internet or telephone?
     
     
     
     
     
     
     
    You may vote by proxy on the internet by following the instructions provided on the proxy card or in the Notice of Internet Availability of Proxy Materials. If you request printed copies of the proxy materials by mail, you may vote by proxy by calling the toll-free number found on the proxy card. Please be aware that if you vote on the internet, you may incur costs such as internet access or telephone charges for which you will be responsible. The internet and telephone voting facilities for eligible shareholders of record will close at 11:59 p.m. Eastern Time on November 18, 2025. The giving of such a proxy by internet or
    telephone will not affect your right to vote in person should you decide to attend the EGM.
    The internet and telephone voting procedures are designed to authenticate shareholders’ identities, to allow shareholders to give their voting instructions and to confirm that shareholders’ instructions have been recorded properly. If you vote by internet or telephone, that vote authorizes your proxy in the same manner as if you signed, dated, and returned a written proxy card by mail.
     
     
     
     
     
     
     
    9.
     
     
    What if I return a proxy card but do not make specific choices?
     
     
     
     
     
     
     
    If we receive a signed and dated proxy card and the proxy card does not specify how your shares are to be voted, your shares will be voted FOR the approval of the reduction of the Company’s capital to facilitate the creation of distributable reserves.
    If any other matter is properly presented at the EGM, your proxy (one of the individuals named on your proxy card) will vote your shares using his or her discretion.
     
     
     
     
     
     
     
    10.
     
     
    Who is paying for this proxy solicitation?
     
     
     
     
     
     
     
    We will pay for the entire cost of soliciting proxies. In addition to these mailed proxy materials, our directors, officers, and employees may also solicit proxies in person, by telephone, or by other means of communication. Directors, officers, and employees will not be paid any
    additional compensation for soliciting proxies. We may also reimburse brokerage firms, banks, and other agents for the cost of forwarding proxy materials to beneficial owners.
     
     
     
     
     
     
     
    11.
     
     
    What does it mean if I receive more than one set of materials?
     
     
     
     
     
     
     
    If you receive more than one set of materials, your shares are registered in more than one name or are registered in different accounts. In order to vote all the shares you own, you must either sign and return all of the proxy cards or
    follow the instructions for any alternative voting procedure on each of the proxy cards or Notice of Internet Availability of Proxy Materials you receive.
     
     
     
     
     
     
     
    12.
     
     
    Can I change my vote after submitting my proxy?
     
     
     
     
     
     
     
    Yes. You may revoke your proxy at any time before commencement of the EGM. If you are the record holder of your shares, you may revoke your proxy in any one of three ways:
    •
    You may submit a new vote on the internet or by telephone or submit another properly completed proxy card with a later date than your original proxy card, but no later than 11:59 p.m. Eastern Time on November 18, 2025.
    •
    You may deliver a written notice that you are revoking your proxy to our Company Secretary at Prothena Corporation plc, 77 Sir John Rogerson’s Quay, Block C,
    Grand Canal Docklands, Dublin 2, D02 VK60, Ireland, which notice must be delivered no later than 11:59 p.m. Eastern Time on November 18, 2025.
    •
    You may attend the EGM and either vote or revoke your proxy in person. Simply attending the EGM will not, by itself, revoke your proxy.
    If your shares are held by your broker, bank, or other agent, you must contact the broker, bank, or other agent and follow the instructions provided by them.
     
     
     
     
     
     
     
    4
     
     

     
     
    2025 PROXY STATEMENT FOR EXTRAORDINARY GENERAL MEETING
     
     
     
     
     
     
     

    TABLE OF CONTENTS

    THE PROXY PROCESS AND SHAREHOLDER VOTING
    QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING
     
     
     
     
     
     
     
    13.
     
     
    What is the quorum requirement?
     
     
     
     
     
     
     
    A quorum of shareholders is necessary to hold a valid meeting. A quorum will be present if the holders of not less than one-half of the ordinary shares issued and outstanding and entitled to vote are present in person or represented by proxy at the EGM. On the Record Date, there were 53,829,928 ordinary shares issued and outstanding and entitled to vote. Accordingly, 26,914,965 ordinary shares must be represented in person or by proxy at the EGM to have a quorum.
    Your shares will be counted towards the quorum if you submit a valid proxy vote or vote at the EGM. Abstentions will also be counted towards the quorum requirement. If there is no quorum, either the chairperson of the EGM or a majority in voting power of the shareholders entitled to vote at the EGM, present in person or represented by proxy, may adjourn the EGM to another time or place.
     
     
     
     
     
     
     
    14.
     
     
    How can I find out the results of the voting at the EGM?
     
     
     
     
     
     
     
    Voting results will be announced by the filing with the SEC of a Current Report on Form 8-K within four business days after the EGM.
     
     
     
     
     
     
     
    15.
     
     
    Where can I find directions to the EGM?
     
     
     
     
     
     
     
    To obtain directions to the EGM, which will be held at the offices of the Company’s legal counsel, A&L Goodbody LLP, 25 North Wall Quay, Dublin 1, D01 H104, Ireland, you
    may send a request to our Company Secretary at Prothena Corporation plc, 77 Sir John Rogerson’s Quay, Block C, Grand Canal Docklands, Dublin 2, D02 VK60, Ireland.
     
     
     
     
     
     
     
    16.
     
     
    When are shareholder proposals and nominations due for next year’s annual general meeting?
     
     
     
     
     
     
     
    In accordance with Rule 14a-8 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), shareholders may submit to us proposals on matters appropriate for shareholder action at meetings of our shareholders. In order to be considered for inclusion in next year’s proxy materials, your proposal must comply with the requirements of Rule 14a-8 of the Exchange Act and other SEC rules and be submitted in writing no later than November 28, 2025, to our Company Secretary at Prothena Corporation plc, 77 Sir John Rogerson’s Quay, Block C, Grand Canal Docklands, Dublin 2, D02 VK60, Ireland; provided that if the date of next year’s annual general meeting of shareholders is greater than 30 days from May 13, 2026, the deadline is a reasonable time before we begin to print and send our proxy materials for next year’s annual general meeting.
    For a shareholder to make any formal nomination of a director candidate for election to the Board at the 2026 annual general meeting of shareholders, the shareholder must provide notice to the Company not earlier than October 29, 2025, and not later than December 28, 2025, and must otherwise comply with the requirements set forth in our Constitution. You are advised to review our Constitution, which contains additional requirements about advance notice of director nominations.
    In addition to satisfying the requirements regarding director nominations in our Constitution, to comply with the universal proxy rules, shareholders who intend to solicit proxies in support of director nominees other than the Company’s nominees must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act no later than March 14, 2026.
     
     
     
     
     
     
     

     
     
    2025 PROXY STATEMENT FOR EXTRAORDINARY GENERAL MEETING
     
     
    5
     
     
     
     
     
     
     

    TABLE OF CONTENTS

     
     
     
     
     
     
     
    PROPOSAL
    NO. 1
     
     
    APPROVAL OF A REDUCTION OF THE
    COMPANY’S CAPITAL TO CREATE
    DISTRIBUTABLE RESERVES
     
     
     
     
     
     
     
    Background
     
    Under Irish law, we may repurchase or redeem our shares, pay dividends, or make other distributions to our shareholders only out of our “distributable reserves”, which generally means accumulated realized profits less accumulated realized losses.
    Irish law permits the Company - subject to the approval of shareholders and the confirmation of the Irish High Court - to reduce all or part of its share premium account and credit the resulting sum to the Company’s profit and loss account.
    At our annual general meeting of shareholders on May 18, 2021, our shareholders approved a reduction of the Company’s capital which was subsequently approved by the Irish High Court on December 14, 2021. As a result of impairments recognized on our investment in subsidiaries, our “distributable reserves” have been reduced and as of December 31, 2024, we had approximately $49.3 million in distributable reserves.
    The amount standing to the credit of the Company’s share premium account as of December 31, 2024, was approximately $479.7 million.
    In order to facilitate the creation of distributable reserves, we are asking our shareholders to approve the reduction of our capital up to the entire balance of our share premium account as of the passing of this resolution, or such lesser amount as our Board may determine or the Irish High Court may confirm. In order to have greater flexibility in the future to execute corporate transactions, including, a potential share redemption program, we are now seeking approval to reduce the capital on the terms set out below.
    Why We are Proposing to Create Distributable Reserves
     
    Our Board reviews the Company’s capital structure and balance sheet strength on a regular basis. We are seeking to create distributable reserves, by way of the proposed reduction of our capital by up to the entire balance of our share premium account as of the passing of this resolution, or such lesser amount as our Board may determine or the Irish High Court may confirm, in order to give our Board flexibility with respect to allocating our capital, such as by allowing it to authorize redemptions or repurchases of our shares, payment of dividends to our shareholders, or other distributions to our shareholders. In particular, the proposed reduction would give our Board the flexibility to potentially return capital to shareholders via a share redemption program through open market purchases or other permissible means as mentioned in our press release issued on August 4, 2025.
    Our Board has not made any final decision to authorize any such return of capital, including a share redemption program, and such an action will depend on prevailing market and economic conditions; our financial position, results of operations, and prospects; our available cash, cash flow, and liquidity requirements; our ordinary share price; capital and regulatory requirements; and other factors, conditions, and circumstances as may be considered by our Board.
    In order to reduce our capital to create distributable reserves, we must seek the Irish High Court’s confirmation of the proposed capital reduction. If shareholders approve this proposal, we currently intend to seek the Irish High Court’s confirmation as soon as practicable. We expect the Irish High Court’s confirmation process to take approximately six to eight weeks from the date of making an application, but it may take longer depending on the Court’s schedule and availability. Although we are not aware of any reason why the Irish High Court would not confirm a reduction of our capital to facilitate the creation of distributable reserves, there is no guarantee of such confirmation or that the Irish High Court will confirm the amount of the capital reduction we seek.
    Even if shareholders approve this proposal, our Board determines to proceed with obtaining the Irish High Court’s confirmation of a reduction in our capital in order to create distributable reserves, and the Irish High Court confirms that reduction in our capital, there is no guarantee that our Board will utilize those distributable reserves by authorizing a share redemption program or any other distribution to our shareholders.
     
     
     
     
     
     
     
    6
     
     

     
     
    2025 PROXY STATEMENT FOR EXTRAORDINARY GENERAL MEETING
     
     
     
     
     
     
     

    TABLE OF CONTENTS

    PROPOSAL NO. 1 – APPROVAL OF A REDUCTION OF THE COMPANY’S CAPITAL TO CREATE DISTRIBUTABLE RESERVES
    For the reasons described above, we are asking shareholders to approve the following special resolution at the EGM:
    RESOLVED, as a special resolution, that:
    Subject to and with confirmation from the Irish High Court, in accordance with sections 84 and 85 of the Irish Companies Act 2014 (the “Act”), the company capital of Prothena Corporation plc (the “Company”) be reduced in the following manner:
    (a)
    Subject to (b) below, the entire amount standing to the credit of the share premium account of the Company immediately preceding the passing of this resolution or such lesser amount as the Irish High Court may determine, be cancelled and extinguished such that the reserve resulting from such cancellation be treated as profits available for distribution as defined by section 117 of the Act; and
    (b)
    The Directors of the Company (or any duly authorised committee thereof) be and they are hereby authorised to determine, on behalf of the Company, to proceed to seek confirmation from the Irish High Court of a reduction of up to the entire amount standing to the credit of the share premium account immediately preceding the passage of this resolution or such lesser amount or number as the Directors of the Company (or any duly authorised committee thereof) may approve in their absolute discretion, or to determine not to proceed to seek confirmation of the Irish High Court at all in pursuance of paragraph (a) above.
    Vote Required; Recommendation of the Board
     
    Under Irish law, this proposal to reduce the Company’s capital constitutes a special resolution that requires the affirmative vote of 75% of the votes cast in person or by
    proxy at the EGM in order to be approved. Abstentions and broker non-votes will not have any effect on the outcome of voting on this proposal.
     
     
     
     
    THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT SHAREHOLDERS VOTE
    FOR APPROVAL OF THE REDUCTION OF THE COMPANY'S CAPITAL TO
    CREATE DISTRIBUTABLE RESERVES.
     
     
     
     
     
     
     
     
     
     
     

     
     
    2025 PROXY STATEMENT FOR EXTRAORDINARY GENERAL MEETING
     
     
    7
     
     
     
     
     
     
     

    TABLE OF CONTENTS

    SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
    The following table presents information as to the beneficial ownership of our ordinary shares as of September 24, 2025, (except as noted) for:
    •
    each person, or group of affiliated persons, known by us to beneficially own more than 5% of our ordinary shares;
    •
    each of our directors;
    •
    each of our executive officers named in the Summary Compensation Table - Fiscal Year 2024; and
    •
    all of our directors and executive officers as a group.
    Unless otherwise indicated, the address of each beneficial owner named below is c/o Prothena Corporation plc, 77 Sir John Rogerson’s Quay, Block C, Grand Canal Docklands, Dublin 2, D02 VK60, Ireland.
     
     
     
     
     
     
     
    Name of Beneficial Owner
     
     
    Amount and Nature of Beneficial Ownership(1)
     
     
    5% Shareholders:
     
     
    Shares
     
     
    Shares
    Acquirable
    Within 60 Days(2)
     
     
    Total Shares
    Deemed
    Beneficially
    Owned
     
     
    Percent of
    Outstanding
    Shares(3)
     
     
    Entities Associated with Fidelity Investments(4)
     
     
    8,049,796
     
     
    —
     
     
    8,049,796
     
     
    15.0%
     
     
    William P. Scully(5)
     
     
    5,351,846
     
     
    —
     
     
    5,351,846
     
     
    9.9%
     
     
    Todd W. Fennell(6)
     
     
    4,350,846
     
     
    —
     
     
    4,350,846
     
     
    8.1%
     
     
    BlackRock, Inc.(7)
     
     
    3,770,650
     
     
    —
     
     
    3,770,650
     
     
    7.0%
     
     
    ADAR1 Capital Management, LLC(8)
     
     
    3,375,009
     
     
    —
     
     
    3,375,009
     
     
    6.3%
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    Directors and Named Executive Officers:
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    Paula K. Cobb
     
     
    —
     
     
    112,500
     
     
    112,500
     
     
    *
     
     
    Richard T. Collier
     
     
    1,219
     
     
    121,741
     
     
    122,960
     
     
    *
     
     
    Shane M. Cooke
     
     
    —
     
     
    121,741
     
     
    121,741
     
     
    *
     
     
    William H. Dunn, Jr.
     
     
    —
     
     
    35,000
     
     
    35,000
     
     
    *
     
     
    Lars G. Ekman
     
     
    243
     
     
    121,741
     
     
    121,984
     
     
    *
     
     
    Helen S. Kim
     
     
    —
     
     
    60,000
     
     
    60,000
     
     
    *
     
     
    Dennis J. Selkoe(9)
     
     
    4,208
     
     
    90,241
     
     
    94,449
     
     
    *
     
     
    Daniel G. Welch
     
     
    —
     
     
    41,400
     
     
    41,400
     
     
    *
     
     
    Gene G. Kinney
     
     
    152,793
     
     
    2,116,234
     
     
    2,269,027
     
     
    4.1%
     
     
    Tran B. Nguyen
     
     
    97,205
     
     
    820,940
     
     
    918,145
     
     
    1.7%
     
     
    Brandon S. Smith
     
     
    130,000
     
     
    446,770
     
     
    576,770
     
     
    1.1%
     
     
    Carol D. Karp
     
     
    —
     
     
    564,581
     
     
    564,581
     
     
    1.0%
     
     
    Wagner M. Zago
     
     
    85,000
     
     
    482,103
     
     
    567,103
     
     
    1.0%
     
     
    All 15 directors and executive officers as a group
     
     
    660,668
     
     
    5,238,050
     
     
    5,898,718
     
     
    10.0%
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    *
    Represents beneficial ownership of less than one percent of our issued and outstanding ordinary shares.
    (1)
    Represents ordinary shares. Beneficial ownership is determined in accordance with U.S. Securities and Exchange Commission (the “SEC”) rules and generally includes voting or investment power. Unless otherwise indicated below, to our knowledge, the persons and entities named in this table have sole voting and sole dispositive power with respect to all shares beneficially owned, subject to community property laws where applicable.
    (2)
    For purposes of this table, a person is deemed to have beneficial ownership of our ordinary shares which such person has the right to acquire on or within 60 days after September 24, 2025. The shares reported in this column consist of shares that may be acquired by exercise of NQSOs (nonqualified stock options) granted under our Amended and Restated 2012 Long Term Incentive Plan, our 2018 Long Term Incentive Plan, as amended, or our 2020 Employment Inducement Incentive Plan, as amended.
     
     
     
     
     
     
     
    8
     
     

     
     
    2025 PROXY STATEMENT FOR EXTRAORDINARY GENERAL MEETING
     
     
     
     
     
     
     

    TABLE OF CONTENTS

    SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
    (3)
    The percentage of outstanding shares is based on the 53,829,928 ordinary shares issued and outstanding on September 24, 2025. However, for purposes of computing the percentage of outstanding ordinary shares beneficially owned by each person or group of persons, any shares which such person or group of persons has a right to acquire on or within 60 days after September 24, 2025, are deemed to be outstanding, but are not deemed to be outstanding for the purpose of computing the percentage of beneficial ownership of any other person.
    (4)
    As reported on Amendment No. 3 to Schedule 13G filed with the SEC on February 9, 2024, by FMR LLC (“FMR”) and Abigail P. Johnson, reporting beneficial ownership as of December 29, 2023. FMR has sole voting power over 8,049,190 ordinary shares and sole dispositive power over 8,049,796 ordinary shares. Ms. Johnson and members of the Johnson family control 49% of FMR and have shared voting and dispositive power over the shares listed herein. Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of ordinary shares. According to FMR’s most recent Form 13F filed with the SEC on August 14, 2025, reporting the securities it held as of June 30, 2025, FMR reported ownership of 7,901,218 ordinary shares (or 14.7% of our outstanding shares as of September 24, 2025). The address of the beneficial owners is 245 Summer Street, Boston, Massachusetts 02210, USA.
    (5)
    As reported on Amendment No. 4 to Schedule 13G filed with the SEC on August 13, 2025, by William P. Scully, reporting beneficial ownership as of June 30, 2025. Mr. Scully has sole voting power and sole dispositive power over 768,000 ordinary shares, and has shared voting power and shared dispositive power over 4,583,846 ordinary shares, consisting of (i) 5,000 Ordinary Shares owned directly by the Reporting Person over which he has sole voting and dispositive power, (ii) 80,000 Ordinary Shares owned by Manatee Equity Fund LLC, of which the Reporting Person is the sole manager with sole voting and dispositive power, (iii) 683,000 Ordinary Shares owned by the Reporting Persons IRA, over which he has sole voting and dispositive power, (iv) 42,000 Ordinary Shares owned by the Reporting Persons spouses IRA, over which he may be deemed to have shared voting and dispositive power, (v) 10,000 Ordinary Shares owned by the Reporting Persons spouse, over which he may be deemed to have shared voting and dispositive power (vi) 23,000 Ordinary Shares owned by an IRA subject to an investment management agreement over which the Reporting Person may be deemed to have shared voting and dispositive power by reason of his right to terminate such agreement, (vii) 158,000 Ordinary Shares owned in the aggregate by various trusts, of which the Reporting Person may be deemed to have shared voting and dispositive power by virtue of being a co-trustee, (viii) 4,310,846 Ordinary Shares owned in the aggregate by various grantor retained annuity trusts, which have an independent trustee, but over which the Reporting Person may be deemed to have shared voting and dispositive power by reason of his retained right to substitute assets in such trusts, and (ix) 40,000 Ordinary Shares owned in the aggregate by various other trusts, which have an independent trustee, but over which the Reporting Person may be deemed to have shared voting and dispositive power by reason of his retained right to substitute assets in such trusts. The address of the beneficial owners is 771 Manatee Cove, Vero Beach, Florida 32963, USA.
    (6)
    As reported on Amendment No. 4 to Schedule 13G filed with the SEC on August 13, 2025, by Todd W. Fennell, reporting beneficial ownership as of June 30, 2025. Todd W. Fennell has shared voting and dispositive power over 4,350,846 ordinary shares, consisting of (i) 40,000 ordinary shares owned by an irrevocable gift trust, for which Mr. Fennell serves as an independent trustee, and (ii) 4,310,846 ordinary shares owned in the aggregate by various grantor retained annuity trusts, for which Mr. Fennell serves as an independent trustee. The address of the beneficial owner is 979 Beachland Boulevard, Vero Beach, Florida 32963, USA.
    (7)
    As reported on Amendment No. 9 to Schedule 13G filed with the SEC on February 2, 2024, by BlackRock, Inc. (“BlackRock”), reporting beneficial ownership of December 31, 2023. BlackRock, Inc. is a parent holding company/control person that has sole voting power over 3,684,648 ordinary shares and sole dispositive power over 3,770,650 ordinary shares. Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the ordinary shares; no one person’s interest in those ordinary shares is more than five percent of the total outstanding ordinary shares. The subsidiaries holding the shares reported herein are BlackRock Life Limited; BlackRock Advisors, LLC; Aperio Group, LLC; BlackRock (Netherlands) B.V.; BlackRock Institutional Trust Company, National Association; BlackRock Asset Management Ireland Limited; BlackRock Financial Management, Inc.; BlackRock Japan Co., Ltd; BlackRock Asset Management Schweiz AG; BlackRock Investment Management, LLC; BlackRock Investment Management (UK) Limited; BlackRock Asset Management Canada Limited; BlackRock Investment Management (Australia) Limited; BlackRock Fund Advisors; and BlackRock Fund Managers Ltd. According to BlackRock’s most recent Form 13F filed with the SEC on August 12, 2025, reporting the securities it held as of June 30, 2025, BlackRock reported ownership of 3,939,398 ordinary shares (or 7.3% of our outstanding shares as of September 24, 2025). The address of the beneficial owner is 50 Hudson Yards, New York, NY 10001, USA.
    (8)
    As reported on Schedule 13G filed with the SEC on August 14, 2025, by ADAR1 Capital Management, LLC (“ADAR1”), ADAR1 Capital Management GP, LLC (“ADAR1 GP”), and Daniel Schneeberger, reporting beneficial ownership as of June 30, 2025. ADAR1 has shared voting and dispositive power over 3,375,009 ordinary shares, consisting of (i) 2,892,995 ordinary shares owned by ADAR1 Partners, LP (ADAR1 LP”) and (ii) 482,014 ordinary shares held by Spearhead Insurance Solutions IDF, LLC (“Spearhead”) as of June 30, 2025. As the investment manager of ADAR1 LP and as the sub-advisor of Spearhead, ADAR1 may be deemed to indirectly beneficially own securities held by ADAR1 LP and Spearhead. ADAR1 GP has shared voting and dispositive power over 2,892,995 ordinary shares, all of which are held by ADAR1 Partners, LP as of June 30, 2025. ADAR1 GP, as the general partner of ADAR1 LP, may be deemed to indirectly beneficially own securities held by ADAR1 LP. Mr. Daniel Schneeberger has shared voting and dispositive power over 2,892,995 ordinary shares, consisting of (i) 2,892,995 ordinary shares held by ADAR1 LP and (ii) 482,014 ordinary shares held by Spearhead as of June 30, 2025. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 LP and Spearhead. The address of the beneficial owners is 3503 Wild Cherry Drive, Building 9, Austin, Texas 78738, USA.
    (9)
    Includes 2,845 ordinary shares held by Dr. Selkoe and 1,363 ordinary shares held by Dr. Selkoe’s spouse.
     
     
     
     
     
     
     

     
     
    2025 PROXY STATEMENT FOR EXTRAORDINARY GENERAL MEETING
     
     
    9
     
     
     
     
     
     
     

    TABLE OF CONTENTS

    HOUSEHOLDING OF PROXY MATERIALS
    The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for Notices of Internet Availability of Proxy Materials or other EGM materials with respect to two or more shareholders sharing the same address by delivering a single Notice of Internet Availability of Proxy Materials or other EGM materials addressed to those shareholders. This process, which is commonly referred to as “householding,” potentially means extra convenience for shareholders and cost savings for companies.
    Brokers with account holders who are Prothena shareholders may be “householding” our proxy materials. A single Notice of Internet Availability of Proxy Materials or other EGM materials may be delivered to multiple shareholders sharing an address unless contrary instructions have been received from the affected shareholders. Once you have received notice from your broker that it will be “householding” communications to your address, “householding” will continue until you are notified otherwise or until you notify your broker or the Company that you no longer wish to participate in “householding.”
    If, at any time, you no longer wish to participate in “householding” and would prefer to receive a separate Notice of Internet Availability of Proxy Materials or other EGM materials, you may (a) notify your broker, (b) direct your written request to our Company Secretary at Prothena Corporation plc, 77 Sir John Rogerson’s Quay, Block C, Grand Canal Docklands, Dublin 2, D02 VK60, Ireland, or (c) contact Prothena Investor Relations by telephone at (650) 837-8535 (a U.S. telephone number). Shareholders who currently receive multiple copies of the Notice of Internet Availability of Proxy Materials or other EGM materials at their address and would like to request “householding” of their communications should contact their broker. In addition, the Company will promptly deliver, upon written or oral request to the address or telephone number above, a separate copy of the Notice of Internet Availability of Proxy Materials or other EGM materials to a shareholder at a shared address to which a single copy of the documents was delivered.
     
     
     
     
     
     
     
     
     
     
    By Order of the Board of Directors
     
     
     
     
     

     
     
     
     
     
     
    Michael J. Malecek
    Chief Legal Officer & Company Secretary
    Dublin, Ireland
    [ ], 2025
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    10
     
     

     
     
    2025 PROXY STATEMENT FOR EXTRAORDINARY GENERAL MEETING
     
     
     
     
     
     
     

    TABLE OF CONTENTS


     

    TABLE OF CONTENTS


     
    Get the next $PRTA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRTA

    DatePrice TargetRatingAnalyst
    5/28/2025$4.00Neutral → Underperform
    BofA Securities
    5/27/2025Outperform → Perform
    Oppenheimer
    5/27/2025$6.00Buy → Hold
    Jefferies
    5/27/2025Overweight → Neutral
    Cantor Fitzgerald
    12/20/2024$40.00Buy
    Chardan Capital Markets
    1/30/2024$68.00 → $38.00Buy → Neutral
    BofA Securities
    12/12/2023$62.00Buy
    Deutsche Bank
    4/24/2023$80.00Outperform
    SVB Securities
    More analyst ratings

    $PRTA
    SEC Filings

    View All

    SEC Form PRE 14A filed by Prothena Corporation plc

    PRE 14A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)

    9/25/25 4:30:36 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Prothena Corporation plc

    8-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)

    8/27/25 4:15:38 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Prothena Corporation plc

    SCHEDULE 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)

    8/14/25 1:07:20 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Prothena downgraded by BofA Securities with a new price target

    BofA Securities downgraded Prothena from Neutral to Underperform and set a new price target of $4.00

    5/28/25 8:10:50 AM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prothena downgraded by Oppenheimer

    Oppenheimer downgraded Prothena from Outperform to Perform

    5/27/25 9:09:16 AM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prothena downgraded by Jefferies with a new price target

    Jefferies downgraded Prothena from Buy to Hold and set a new price target of $6.00

    5/27/25 9:09:16 AM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Zago Wagner M. was granted 85,000 units of Ordinary Shares (SEC Form 4)

    4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)

    7/30/25 5:52:29 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Accounting Officer Walker Karin L was granted 25,000 units of Ordinary Shares (SEC Form 4)

    4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)

    7/30/25 5:52:14 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Development Officer Swanson Chad J. was granted 85,000 units of Ordinary Shares (SEC Form 4)

    4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)

    7/30/25 5:52:01 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference

    Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 4, 2025 at 10:55 a.m. ET in New York, NY. A live webcast of the fireside chat can be accessed through the investor relations section of the Company's website at www.prothena.com. Following the live presentation, a replay of the webcast will be available on the Company's website for 90 days following the presentation date. About Prothena P

    8/28/25 4:05:00 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program

    As previously communicated, Prothena plans to explore potential partnership interest to advance PRX012 and its preclinical PRX012-TfR (transferrin receptor) antibody Phase 1 ASCENT clinical program established proof-of-mechanism for PRX012 as a once-monthly, subcutaneous anti-amyloid beta antibody with high binding potency, dose- and time-dependent reduction of amyloid plaque, although with a non-competitive ARIA-E profile in patients with early symptomatic Alzheimer's disease Prothena Corporation plc (NASDAQ:PRTA), today announced results from the Phase 1 ASCENT clinical program in participants with early symptomatic Alzheimer's disease (AD). As previously communicated, Prothena pl

    8/27/25 4:05:00 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy

    Coramitug is a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3 Novo Nordisk successfully completed a Phase 2 trial with coramitug and is expected to initiate a Phase 3 program in 2025 Prothena to earn a clinical milestone payment when prespecified enrollment criteria are met in a Phase 3 clinical trial by Novo Nordisk Prothena Corporation plc (NASDAQ:PRTA), announced that Novo Nordisk communicated during their second quarter 2025 earnings call on August 6, 2025 that they expect to advance coramitug, a potential first-in-class amyloid depleter antibody, into a Phase 3 program for ATTR amyloidosis with cardiomyopathy (A

    8/6/25 9:00:00 AM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Scully William P received a gift of 430,000 units of Ordinary Shares, bought $2,749,916 worth of Ordinary Shares (207,436 units at $13.26) and gifted 747,700 units of Ordinary Shares, decreasing direct ownership by 7% to 735,993 units (SEC Form 4)

    4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)

    5/2/25 10:29:05 AM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTA
    Leadership Updates

    Live Leadership Updates

    View All

    Prothena Reports Third Quarter 2024 Financial Results and Business Highlights

    Net cash used in operating and investing activities was $45.2 million and $102.5 million for the third quarter and first nine months of 2024, respectively; quarter-end cash and restricted cash position was $520.1 million PRX012, a potential single-injection once-monthly subcutaneous treatment, is designed to address the unmet need of millions of patients with presymptomatic or early symptomatic Alzheimer's disease; Prothena expects to report multiple clinical readouts starting in mid-2025 and continuing throughout the year from the ongoing Phase 1 ASCENT clinical trials Results from partner Roche evaluating prasinezumab in patients with early Parkinson's disease from the Phase 2 PASA

    11/12/24 4:05:00 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prothena Reports First Quarter 2024 Financial Results and Business Highlights

    Net cash used in operating and investing activities was $73.2 million in the first quarter of 2024; quarter-end cash and restricted cash position was $548.7 million Advanced potential best-in-class Alzheimer's disease portfolio: initial data supportive of ongoing Phase 1 clinical trial for PRX012, an anti-amyloid beta antibody; received FDA clearance for IND application and Fast Track designation for PRX123, a dual amyloid beta/tau vaccine; Phase 2 clinical trial initiated in patients with early Alzheimer's disease for BMS-986446 (formerly PRX005) by partner Bristol Myers Squibb Strengthened leadership position in the amyloidosis community with ongoing enrollment of the confirmatory

    5/8/24 4:05:00 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prothena Appoints David Ford to Newly Created Chief People Officer Position

    Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it has named David Ford to a newly created position of Chief People Officer, reporting to Prothena President and Chief Executive Officer Gene Kinney, PhD. In this role, Mr. Ford will be responsible for people, culture, and human resources strategy to drive the company's vision and overall growth strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240304692974/en/David Ford, Chief People Officer, Prothena (Photo: Business Wire

    3/4/24 4:05:00 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Prothena Corporation plc

    SC 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)

    11/14/24 1:22:34 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Prothena Corporation plc

    SC 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)

    11/13/24 7:00:50 AM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Prothena Corporation plc

    SC 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)

    11/13/24 6:06:27 AM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTA
    Financials

    Live finance-specific insights

    View All

    Prothena to Report Second Quarter 2025 Financial Results on August 4

    Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its second quarter and first six months of 2025 financial results on Monday, August 4, 2025, after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with the financial results release on August 4. About Prothena Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potent

    7/28/25 4:05:00 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prothena to Report First Quarter 2025 Financial Results on May 8

    Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025, after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with the financial results release on May 8. About Prothena Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of deva

    5/1/25 4:05:00 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights

    Net cash used in operating and investing activities was $47.8 million in the fourth quarter and $150.3 million for the full year of 2024; quarter-end cash and restricted cash position was $472.2 million The company expects cash guidance for the full year 2025 net cash used in operating and investing activities to be $168 to $175 million and expects to end the year with approximately $301 million in cash (midpoint) Topline results expected in 2Q 2025 from the confirmatory Phase 3 AFFIRM-AL clinical trial of birtamimab in patients with Mayo Stage IV AL amyloidosis being conducted under a SPA agreement with the FDA with a primary endpoint of all-cause mortality (time-to-event) at a statis

    2/20/25 4:05:00 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care